在不活跃的性结肠炎组织活检中,DNA甲基化微调亲和抗炎信号通路
Wei Meng1, Christopher G Fenton1,2, Kay-Martin Johnsen3,4
1Clinical Bioinformatics Research Group, Department of Clinical Medicine, Faculty of Health Sciences, UiT- The Arctic University of Norway, Tromsø, Norway.
Scientific reports
|March 22, 2024
概括
不活跃的性结肠炎 (UC) 患者的DNA甲基化变化揭示了关键的调节基因. 这些在不活跃UC的发现可能为管理炎症性肠病提供新的治疗点.
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- DNA甲基化与炎症性肠病 (IBD) 中的免疫功能障碍有关.
- 在不活跃的性结肠炎 (UC) 中了解DNA甲基化可能会揭示治疗点.
研究的目的:
- 为了研究DNA甲基化模式和基因表达在不活跃的UC.
- 确定参与维护UC上皮质平衡的甲基化调节基因.
主要方法:
- 针对性双硫酸盐测序和粘膜活检上的全转录组测序.
- 使用DMRseq.进行差异甲基化区域 (DMR) 识别.
- 在DMRs和差异表达基因 (DEGs) 之间的相关性分析.
主要成果:
- 在不活跃的UC中确定了38个甲基化调节基因,这些基因可能由DMRs控制.
- 发现了像IL1B和STAT3这样的基因参与IL-10和细胞因子信号通路.
- 不活跃UC中的DNA甲基化平衡了治疗的亲和抗炎途径.
结论:
- 通过DNA甲基化的表观遗传调节在不活跃的UC中起着至关重要的作用.
- 甲基化模式有助于通过平衡炎症反应来维持上皮质平衡.
- 这些发现表明了UC治疗的潜在治疗策略.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
162
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
162
Inflammatory Bowel Disease I: Ulcerative Colitis
179
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
179
Epigenetic Regulation
31.1K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
31.1K
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127


